All Releases
 |
"Modern Family" Star Julie Bowen Calls on Communities to Raise Their Hand for Anaphylaxis Awareness in Nationwide Competition
May 21, 2013
|
18.0 KB |
|
| |
BASKING RIDGE, N.J., May 21, 2013 /PRNewswire/ -- As part of the national Get Schooled in Anaphylaxis™ initiative, Emmy®-award winning actress Julie Bowen today kicked off Raise Your Hand for Anaphylaxis Awareness™, a community-driven competition designed to bring attention to the issue of life-threatening allergic reactions, or an...
|
|
Federal Appellate Court Rules in Favor of Mylan in Patent Infringement Litigation Relating to Sunovion's Brovana® Product
May 21, 2013
|
7.2 KB |
|
| |
PITTSBURGH, May 21, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that the Court of Appeals for the Federal Circuit has ruled in favor of Mylan Specialty L.P., f/k/a Dey Pharma, L.P. and has reversed the District Court's decision invalidating five of Mylan's patents related to Perforomist®. The Court's reversal of the summary j...
|
|
Mylan Launches Generic Tricor® Tablets
May 17, 2013
|
6.9 KB |
|
| |
PITTSBURGH, May 17, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has shipped Fenofibrate Tablets, 48 mg and 145 mg. Mylan Pharmaceuticals Inc. received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, whic...
|
|
Mylan Launches Generic Zomig® Tablets
May 15, 2013
|
6.7 KB |
|
| |
PITTSBURGH, May 15, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Zolmitriptan Tablets, 2.5 mg and 5 mg. This product is the generic version of IPR Pharmaceut...
|
|
Mylan Reports a 19% Increase in First Quarter 2013 Adjusted Diluted EPS to $0.62
May 2, 2013
|
37.0 KB |
|
| |
PITTSBURGH, May 2, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced its financial results for the three months ended March 31, 2013.
Financial Highlights
Adjusted diluted EPS of $0.62 for the three months ended March 31, 2013 compared to $0.52 for the same prior year period, an increase of 19%
Total revenues of $...
|
|
Deborah Autor, FDA's Deputy Commissioner for Global Regulatory Operations and Policy, to Join Mylan
Apr 30, 2013
|
9.4 KB |
|
| |
PITTSBURGH, April 30, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has appointed Deborah M. Autor as senior vice president, Strategic Global Quality and Regulatory Policy. Autor joins Mylan from the U.S. Food and Drug Administration (FDA), where she served for 11 years, most recently as deputy commissioner for Global Regula...
|
|
Mylan Specialty L.P. Announces 25th Anniversary Celebration of EpiPen® (epinephrine) Auto-Injector
Apr 25, 2013
|
19.6 KB |
|
| |
BASKING RIDGE, N.J., April 25, 2013 /PRNewswire/ -- Mylan Specialty L.P., the fully integrated specialty pharmaceutical business of Mylan Inc. (Nasdaq: MYL), is celebrating the 25th anniversary of the U.S. Food and Drug Administration's (FDA) approval of the EpiPen® (epinephrine) Auto-Injector. This innovative epinephrine auto-injector, the fi...
|
|
Mylan Announces $1 Million Gift to The Pittsburgh Promise Scholarship Fund
Apr 22, 2013
|
7.4 KB |
|
| |
PITTSBURGH, April 22, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has contributed $1 million to The Pittsburgh Promise Scholarship Fund, a scholarship program for Pittsburgh Public School students that advocates for improving the quality of education and increasing the preparedness and diversity of the region's workforce. ...
|
|
Mylan Delivers Much-anticipated "One Pill Once a Day" Triple Fixed-dose Antiretroviral Combination to the South African National Department of Health
Apr 16, 2013
|
7.9 KB |
|
| |
JOHANNESBURG and PITTSBURGH, April 16, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) announced that its subsidiary, Mylan Laboratories Ltd., a leading manufacturer of antiretroviral (ARV) drugs, has delivered, through its South African-based subsidiary Mylan (Proprietary) ...
|
|
Mylan Schedules First Quarter 2013 Financial Results Conference Call and Live Webcast
Apr 9, 2013
|
6.5 KB |
|
| |
PITTSBURGH, April 9, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) announced today that it will host a conference call and live webcast Thursday, May 2, 2013, at 4:30 p.m. ET, to review the company's financial results for the first quarter, which ended March 31, 2013. Mylan will release its financial results on May 2 after the market closes.
...
|
|
Mylan Launches First Generic Version of Zovirax® Ointment
Apr 3, 2013
|
6.6 KB |
|
| |
PITTSBURGH, April 3, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Acyclovir Ointment USP, 5%. This product is the first generic version of Valeant International's...
|
|
Mylan Launches Generic Version of Xopenex® Inhalation Solution
Mar 18, 2013
|
6.6 KB |
|
| |
PITTSBURGH, March 18, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Specialty L.P. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Levalbuterol Inhalation Solution USP, 0.31 mg/3 mL (0.0103%), 0.63 mg/3 mL (0.021%), and 1.25 mg...
|
|
Mylan Announces Fortamet® Settlement Agreement
Mar 13, 2013
|
7.4 KB |
|
| |
PITTSBURGH, March 13, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has entered into a settlement agreement with Shionogi Inc. and Andrx that will resolve patent litigation related to Metformin Hydrochloride Extended-release Tablets USP, 500 mg and 1000 mg. This product is the generic v...
|
|
Mylan Files Annual Report on Form 10-K for Year Ended Dec. 31, 2012
Mar 4, 2013
|
6.4 KB |
|
| |
PITTSBURGH, March 4, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its Annual Report on Form 10-K, containing audited consolidated financial statements for the year ended Dec. 31, 2012, as filed with the U.S. Securities and Exchange Commission on Feb. 28, 2013, is available through its Web site (www.mylan.com). In addition, the...
|
|
Mylan to Acquire Agila to Create Leading Global Injectables Platform
Feb 27, 2013
|
12.2 KB |
|
| |
PITTSBURGH, Feb. 27, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has signed a definitive agreement to acquire Agila Specialties Private Limited, a developer, manufacturer and marketer of high-quality generic injectable products, from Strides Arcolab Limited (BSE: 532531, NSE: STAR) for $1.6 billion in cash. The acquisition...
|
|
Mylan Reports a 23% Increase in Fourth Quarter 2012 Adjusted Diluted EPS to $0.65
Feb 27, 2013
|
47.7 KB |
|
| |
PITTSBURGH, Feb. 27, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced its financial results for the three months and year ended December 31, 2012.
Financial Highlights
Adjusted diluted EPS of $0.65 for the three months ended December 31, 2012 compared to $0.53 for the same prior year period, an increase of 23%
...
|
|
Mylan Launches Generic Antara® Capsules
Feb 25, 2013
|
6.5 KB |
|
| |
PITTSBURGH, Feb. 25, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals has begun shipping Fenofibrate Capsules USP, 43 mg and 130 mg. This product is the generic version of Lupin Atlantis Holdings, S.A.'s Antara® Capsules, which are indicated as an adjunct to diet to reduce elevated LDL-C, ...
|
|
Mylan Launches Innovative Portfolio of Antiretroviral Products for Treatment of HIV/AIDS in South Africa
Feb 23, 2013
|
8.3 KB |
|
| |
JOHANNESBURG and PITTSBURGH, Feb. 23, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that its subsidiary in South Africa, Mylan (Proprietary) Limited, has launched a comprehensive portfolio of antiretroviral (ARV) products. South Africa has the world's larges...
|
|
Thousands of Schools Nationwide are Receiving Free EpiPen(R) (epinephrine) Auto-Injectors Through the Mylan Specialty L.P. EpiPen4Schools(TM) Program
Feb 20, 2013
|
17.2 KB |
|
| |
BASKING RIDGE, N.J., Feb. 20, 2013 /PRNewswire/ -- Since Mylan Specialty L.P., the fully-integrated specialty pharmaceutical business of Mylan Inc. (Nasdaq: MYL), launched the EpiPen4Schools™ program in August 2012, thousands of schools across the country have elected to participate and redeem free EpiPen® or EpiPen Jr® (epinephrine...
|
|
Mylan Enhances Partnership with Biocon through Strategic Collaboration for Insulin Products
Feb 13, 2013
|
10.3 KB |
|
| |
PITTSBURGH, Feb. 13, 2013 /PRNewswire/ -- Mylan (Nasdaq: MYL) today announced that it has entered into a definitive agreement with Biocon Limited for an exclusive strategic collaboration on the development and commercialization of generic versions of three insulin analog products.
Mylan CEO Heather Bresch commented, "This collaboration ...
|
|
|